Use of Clonazepam (Klonopin) in the Management of Vertigo

Indications for Short‑Term Benzodiazepine Use

The American Academy of Otolaryngology‑Head and Neck Surgery (AAO‑HNS) recommends offering a limited course of benzodiazepines for short‑term symptom control during severe acute vestibular attacks, with treatment duration not exceeding 3–5 days. 1
In patients with Ménière’s disease, benzodiazepines may be offered only during acute attacks and should not be used as continuous therapy. [1][2]
For vestibular neuritis or Ménière’s disease presenting with severe, disabling symptoms that prevent normal functioning, a short‑term benzodiazepine trial is appropriate. [1][2]

The AAO‑HNS explicitly advises against routine treatment of benign paroxysmal positional vertigo (BPPV) with benzodiazepines or any vestibular suppressants. 3
Benzodiazepines are contraindicated during vestibular rehabilitation therapy because they impede the central compensation process essential for long‑term recovery. 1
Vestibular suppressants, including benzodiazepines, should be withdrawn as soon as possible—preferably after the first several days—to avoid interference with central vestibular compensation. [1][4]

Benzodiazepine use is an independent risk factor for falls, especially in older adults who already have an elevated fall risk from vertigo. [1][4]
Common adverse effects include drowsiness, cognitive impairment that can affect driving or operation of machinery, and the potential for dependence with prolonged use. 1
In elderly patients taking multiple medications, benzodiazepines raise the likelihood of drug‑drug interactions, particularly with cardiovascular agents. 1

BPPV: Do not prescribe clonazepam; perform canalith repositioning maneuvers (e.g., Epley, Semont), which achieve ≈80 % success. 2
Severe Acute Vertigo (e.g., vestibular neuritis, Ménière’s attack): Consider a short‑term benzodiazepine course (≤5 days) only when symptoms are disabling. [1][2]
Prescription Criteria: Limit use to patients with severe, disabling vertigo that impairs daily functioning; avoid use as prophylaxis except in patients with a documented history of severe nausea during repositioning procedures. [3][1]
Transition to Definitive Therapy: Initiate vestibular rehabilitation exercises within the first week after acute symptoms subside and discontinue benzodiazepines before starting rehabilitation. Re‑evaluate patients within one month to document symptom resolution or persistence. [1][2]

BPPV: First‑line canalith repositioning maneuvers (Epley, Semont) with ≈80 % success rates; medication alone yields only ~30 % improvement. 2
Severe Nausea/Vomiting: Prochlorperazine 5–10 mg is preferred over benzodiazepines. [1][2]
Non‑BPPV Peripheral Vertigo: As‑needed meclizine (25–100 mg) is favored over benzodiazepines for most patients. [1][2]
Long‑Term Management: Vestibular rehabilitation therapy is more effective than prolonged medication use for sustained symptom control. 2

The American Academy of Otolaryngology–Head and Neck Surgery (AAO‑HNS) clinical practice guidelines (2017) strongly recommend against routine use of antihistamines as vestibular suppressants for most causes of acute vertigo. 5
The AAO‑HNS guidelines specifically advise against routine treatment of benign paroxysmal positional vertigo (BPPV) with any vestibular‑suppressant medication, including antihistamines. 5

Vestibular‑suppressant antihistamines delay central vestibular compensation and increase fall risk, particularly in older adults, according to AAO‑HNS guidance. 6
Sedation and cognitive impairment from antihistamines adversely affect driving ability and daily functioning, as noted by the AAO‑HNS. 6

Canalith repositioning maneuvers (e.g., Epley, Semont) achieve 78.6–93.3 % symptom improvement, far exceeding the ~30.8 % improvement seen with medication alone, per AAO‑HNS evidence. 6
Overall, repositioning maneuvers are approximately 80 % effective for BPPV and should be the sole initial therapy; medications are reserved only for severe nausea during or after the procedure. [5][6]

In cases of severe disabling vertigo during acute vestibular neuritis or Ménière’s disease attacks, short‑term use of first‑generation antihistamines (e.g., meclizine) may be justified as a temporizing measure, per AAO‑HNS guidance. 6
Prophylactic antihistamine administration before repositioning maneuvers may be considered for patients with a documented history of severe nausea during prior procedures. 6
For patients who refuse repositioning maneuvers, a short course of antihistamine can be offered, acknowledging its limited efficacy. 6